AstraZeneca ((AZN)), Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The MAVRiC Study, officially titled ‘A Phase II Study of Disease Risk Mutation Guided Finite Duration Acalabrutinib Plus Venetoclax for Relapse in CLL/SLL After First-line Finite Covalent BTKi Plus BCL2i Combination, With or Without Obinutuzumab,’ aims to evaluate the efficacy and safety of acalabrutinib plus venetoclax in patients with relapsed Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). This study targets patients who have previously responded to first-line therapy and maintained a response for at least two years.
Intervention/Treatment: The study tests two drugs: Acalabrutinib, a BTK inhibitor that disrupts B-cell signaling, and Venetoclax, which inhibits the BCL-2 protein. Both are administered orally and aim to treat relapsed CLL/SLL effectively.
Study Design: This Phase II interventional study is non-randomized with a single-group assignment. There is no masking involved, meaning all participants and researchers know the treatments being administered. The primary purpose is treatment-focused.
Study Timeline: The study is not yet recruiting, with an initial submission date of May 26, 2025, and the latest update on August 29, 2025. These dates are crucial as they indicate the study’s progress and readiness to begin participant recruitment.
Market Implications: This update may influence AstraZeneca and AbbVie’s stock performance positively, as successful results could enhance their market positions in the oncology sector. Investors should monitor this study’s progress, as positive outcomes could lead to increased demand for these treatments, impacting stock valuations.
The study is ongoing, with further details available on the ClinicalTrials portal.